The SEAMARK study validated that combining a BRAF inhibitor (encorafenib), an EGFR inhibitor (cetuximab), and immunotherapy (pembrolizumab) provides a promising therapeutic direction for BRAF‐mutant CRC, ensuring both efficacy and safety in clinical trials [209]. This evidence concerns the gene EGFR and colorectal carcinoma.